Emergent Biosolutions, Inc. (EBS) Dividend History

Company News

• Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

  Emergent BioSolutions has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for approximately $36.5 million. The deal enables Emergent to streamline operations while maintaining flexibility for future product demand.

  Benzinga
• Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

  Emergent BioSolutions and Rocketvax have announced a strategic partnership, where Emergent will invest in Rocketvax and lead the U.S. manufacturing and commercialization of four of Rocketvax's pipeline candidates for infectious diseases, cancer, and autoimmune disorders.

  GlobeNewswire Inc.
• Why Emergent BioSolutions Stock Blasted Higher Today

  Emergent BioSolutions stock surged nearly 12% after an analyst at H.C. Wainwright initiated coverage with a buy recommendation and a $15 price target, citing the company's diversified offerings and growth potential in its Narcan opioid reversal spray and vaccines business.

  The Motley Fool
• 3 Promising Vaccine Stocks to Watch in the Event of an Mpox Surge

  The article discusses three pharmaceutical companies with potential to meet the demand for mpox vaccines: Bavarian Nordic, Emergent Biosolutions, and SIGA Technologies. It highlights their vaccine and treatment candidates, recent developments, and stock performance.

  Investing.com

  Featured Companies: SIGA
• Myriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound?

  Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  Zacks Investment Research

  Featured Companies: MYGN